Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Diffuse Malignant Peritoneal Mesothelioma: Systematic Review Of Clinical Management And Biological Research

D. Baratti, S. Kusamura, M. Deraco
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and locally aggressive tumor with poor prognosis. Currently, no standard therapy is available. The biology of this disease is still poorly understood. We performed a systematic search of relevant studies on clinical management and biological research of DMPM. Trials were selected using a predetermined protocol. The current evidence suggests that cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) results in improved survival. Biological understanding of DMPM is currently evolving. J. Surg. Oncol. 2011;103:822–831. © 2011 Wiley‐Liss, Inc.
This paper references
10.1016/J.EJSO.2006.03.009
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
R. García-Carbonero (2006)
10.1038/nrm830
Apoptosis: IAP proteins: blocking the road to death's door
G. Salvesen (2002)
10.1016/S0002-9440(10)63710-8
Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically.
E. Montgomery (2004)
10.1097/00006254-198403000-00020
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
R. Bast (1983)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
[Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].
G. Passot (2008)
10.1038/nrc968
Validating survivin as a cancer therapeutic target
D. Altieri (2003)
10.1245/s10434-010-1080-6
Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin
Aaron U. Blackham (2010)
10.1245/s10434-006-9169-7
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
T. Yan (2006)
10.1038/nrc2275
Telomerase and cancer therapeutics
C. Harley (2008)
10.1046/J.1365-2168.2000.01571.X
Results of treatment of 33 patients with peritoneal mesothelioma
G. Sebbag (2000)
10.1074/jbc.M806776200
A Binding Domain on Mesothelin for CA125/MUC16*
O. Kaneko (2009)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1006/EXCR.2000.5149
p16(MTS-1/CDKN2/INK4a) in cancer progression.
J. Rocco (2001)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
[Peritoneal mesothelioma].
R. Osieka (1980)
10.1159/000199880
Malignant peritoneal mesothelioma: a series of 19 cases.
T. van Gelder (1989)
10.1016/j.ejca.2010.06.130
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
F. Perrone (2010)
10.1158/1078-0432.CCR-09-0062
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
R. Kreitman (2009)
10.1002/bjs.5863
Learning curve of combined modality treatment in peritoneal surface disease
R. M. Smeenk (2007)
10.1007/s10434-999-0582-6
Treatment of Primary Peritoneal Mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP)
B. Park (1999)
10.1016/j.lungcan.2009.07.016
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
R. Hassan (2010)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Telomerase and cancer.
R. Reddel (1997)
10.1016/S0959-8049(97)00370-5
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
P. van de Vaart (1998)
10.1200/JCO.2007.15.2868
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
G. Simon (2008)
[Peritoneal mesothelioma--incidence and etiology].
V. Neumann (1999)
10.1056/NEJM198310133091503
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
R. Bast (1983)
10.1016/S0021-7697(08)74654-4
Mésothéliome péritonéal : traitement par l’association chirurgie de cytoréduction et chimiothérapie hyperthermique intrapéritonéale
G. Passot (2008)
10.1016/S0009-739X(07)71268-X
Mesotelioma peritoneal maligno. Nuestra experiencia con la triple terapia combinada: citorreducción, quimioterapia intraperitoneal perioperatoria e hipertermia
A. Portilla (2007)
10.1007/BF01225271
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
M. Markman (2005)
10.1200/JCO.2003.04.150
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
A. Feldman (2003)
10.1158/1535-7163.MCT-08-1188
The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel
Erin M. Goldblatt (2009)
Letter: A modified national dried milk.
A. G. Campbell (1975)
An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma.
S. Orii (2003)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1002/1097-0142(19870601)59:11<1882::AID-CNCR2820591107>3.0.CO;2-0
Long‐term survival in peritoneal mesothelioma the role of radiotherapy and combined modality treatment
G. Lederman (1987)
In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C.
B. Barlogie (1980)
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
G. Los (1992)
Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.
G. Los (1990)
10.17925/OHR.2006.00.02.30
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.
T. Yan (2007)
10.1245/s10434-008-0206-6
Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma
J. Foster (2008)
10.1043/1543-2165(2006)130[1654:PSOHPI]2.0.CO;2
Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma.
C. Cerruto (2006)
10.1016/j.ejso.2010.07.001
Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials.
M. Kluger (2010)
10.1007/BF00685836
Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach
C. Langer (2004)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1016/S1055-3207(03)00045-0
A review of peritoneal mesothelioma at the Washington Cancer Institute.
P. Sugarbaker (2003)
10.1002/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.0.CO;2-X
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma
G. Eltabbakh (1999)
10.1002/jso.21055
Consensus statement on peritoneal mesothelioma
M. Deraco (2008)
Intracavitary cisplatin for malignant mesothelioma : an update
S Kirmani (1988)
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma — a multi - institutional registry study
TD Yan (2009)
Systemic chemotherapy with pemetrexed and cisplatin for malignant mesothelioma : a single institution experience
G Lainakis
p 16 ( MTS - 1 / CDKN 2 / INK 4 a ) in cancer progression
JW Rocco (2001)
10.1200/JCO.2006.24.18_SUPPL.9549
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.
G. Antonini Cappellini (2006)
10.1097/00000658-199501000-00004
Peritonectomy Procedures
P. Sugarbaker (2003)
10.1097/00007611-196701000-00012
Diffuse malignant mesothelioma of the peritoneum.
Giles Td (1967)
10.1016/j.lungcan.2008.08.013
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
G. Cartenì (2009)
10.1074/jbc.M312372200
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion*
A. Rump (2004)
10.1080/10408440903044928
Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005
B. Price (2009)
p 16 alterations and deletion mapping of 9 p 21p 22 in malignant mesothelioma
JQ Cheng (1994)
10.1002/jso.21177
Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience
T. Chua (2009)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
10.1007/s002920050340
Peritoneale Mesotheliome – Häufigkeiten und Ätiologie
V. Neumann (1999)
10.1081/CNV-120023766
Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma
D. T. Le (2003)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Trattamento del mesotelioma peritoneale mediante citoriduzione e chemioiperter - mia intraperitoneale ( CIIP )
D Costamagna (2003)
10.1158/1078-0432.CCR-08-0099
Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma
R. Villa (2008)
10.1155/2007/456839
Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma
N. Zaffaroni (2007)
10.1038/sj.onc.1209809
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
A. Borczuk (2007)
Advanced in malignant mesothelioma
Robinson BWS (2005)
Undertaking Systemic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or
(2001)
10.1007/s00280-006-0243-4
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
[Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy].
D. Costamagna (2003)
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
J. Henson (2005)
10.1093/ANNONC/MDL060
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
R. Hassan (2006)
10.1245/s10434-010-0973-8
HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises
G. Baltogiannis (2010)
10.1016/j.ejso.2008.09.010
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
H. Yano (2009)
10.1016/S0399-8320(07)73964-7
Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.
D. Elias (2007)
10.1016/S1055-3207(03)00029-2
Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents.
R. Sticca (2003)
10.1200/JCO.2005.11.030
Proteasome inhibition as a novel therapeutic target in human cancer.
S. Rajkumar (2005)
Sugarbaker PH: Peritonectomy procedures
(1995)
An Italian Multicentric Phase II study on peritonectomy and intra peritoneal Journal of Surgical Oncology hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma
M Deraco (2003)
10.1016/S0140-6736(85)90526-4
EARLY PERITONEAL MESOTHELIOMA: A TREATABLE MALIGNANCY
K. Antman (1985)
10.1126/SCIENCE.7605428
Specific association of human telomerase activity with immortal cells and cancer.
N. Kim (1994)
10.1016/S0092-8674(00)00008-8
Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition
C. Du (2000)
10.1002/1097-0142(197309)32:3<656::AID-CNCR2820320319>3.0.CO;2-U
Long‐term survival in patients with malignant peritoneal mesothelioma treated with irradiation
E. Rogoff (1973)
10.1002/cncr.20836
Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy
T. Yan (2005)
p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.
J. Cheng (1994)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1097/SLA.0b013e3181a45d86
Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality
T. Chua (2009)
Prospective trial for the treatment of malignant peritoneal mesothelioma.
B. Loggie (2001)
10.1245/s10434-006-9187-5
Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma—A Prospective Study of 70 Consecutive Cases
T. Yan (2006)
A binding domain on meso - thelin for CA 125 / MUC 16
R Hassan (2009)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1016/S0009-739X(07)71268-X
[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
A. Gómez Portilla (2007)
10.3816/CLC.2005.N.020
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
P. Jänne (2005)
10.1007/BF00686048
Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatment
G. Los (2004)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1245/s10434-009-0756-2
Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma
D. Baratti (2009)
10.1093/annonc/mdp307
Malignant peritoneal mesothelioma: a multicenter study on 81 cases.
V. Manzini (2010)
10.1002/cncr.21239
Diffuse malignant mesothelioma of the peritoneum
D. Nonaka (2005)
10.1016/S1470-2045(04)01492-5
Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
D. Fennell (2004)
10.1158/1078-0432.CCR-04-1884
P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma
A. Borczuk (2005)



This paper is referenced by
10.1016/J.GASTRE.2016.02.001
Peritoneal mesothelioma unmasked by an acute appendicitis
Eduardo Valdivielso Cortázar (2016)
10.4161/cbt.22622
Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer
Sarah L. Suchy (2013)
10.1021/jm400842x
Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.
A. Carbone (2013)
10.3747/co.23.2831
Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives.
J. Spiliotis (2016)
10.1002/bjs5.50256
Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video‐conference meeting
A. Brandl (2020)
10.1080/15384047.2019.1647053
Meningeal metastasis of a malignant peritoneal mesothelioma: A case report and literature review
Yaofei Jiang (2019)
10.1245/s10434-019-07409-5
50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience
Allison S. Letica-Kriegel (2019)
10.1007/s11547-015-0609-y
CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis
W. Yin (2015)
10.1007/978-3-319-16205-8
Current Controversies in Cancer Care for the Surgeon.
Katherine A. Morgan (2016)
10.1016/j.soc.2018.02.009
Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers.
S. Kusamura (2018)
10.1245/s10434-014-3803-6
Current Trends in the Management of Malignant Peritoneal Mesothelioma
J. Miura (2014)
10.1097/MCG.0b013e318297fa65
Serum HMGB1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
C. Tabata (2013)
10.3844/AMJSP.2012.240.248
The Role of Inflammation in Development and Therapy of Malignant Mesothelioma
Jill M. Miller (2012)
10.3109/07357907.2013.830734
Clinical Significance of Serum Angiopoietin-1 in Malignant Peritoneal Mesothelioma
K. Mikami (2013)
10.1245/s10434-012-2237-2
Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study
D. Baratti (2012)
10.20524/aog.2018.0305
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives
S. Boussios (2018)
10.9738/INTSURG-D-14-00138.1
Hemodynamic Monitoring During Heated Intraoperative Intraperitoneal Chemotherapy Using the FloTrac/Vigileo System.
Christos Mavroudis (2015)
10.1097/MPH.0000000000000262
Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion
Steve Taylor (2015)
10.1259/bjr.20170361
Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.
A. Chandramohan (2017)
10.1016/J.GASTROHEP.2015.01.008
Mesotelioma epitelioide peritoneal desenmascarado por una apendicitis aguda
Eduardo Valdivielso Cortázar (2016)
10.1097/MCG.0b013e31824e901b
Serum Thioredoxin-1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
C. Tabata (2013)
10.1515/pp-2016-0007
Comparative genetics of diffuse malignant mesothelioma tumors of the peritoneumand pleura, with focus on BAP1 expression
M. Brevet (2016)
10.1016/j.ejso.2018.02.010
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Federica Bruno (2018)
10.3892/or.2012.1725
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Neetu Kalra (2012)
10.1080/15384047.2016.1145850
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration
A. Borczuk (2016)
10.1002/jso.24960
Comparison of open and closed abdomen techniques for the delivery of intraperitoneal pemetrexed using a murine model
D. Badrudin (2018)
10.5430/CRCP.V2N1P75
Malignant peritoneal mesothelioma with possible hormone association and multiple endocrine neoplasia in a young female with an indolent clinical course
J. Kling (2014)
10.1309/AJCPOATJ9L4GCGDA
p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
T. Ito (2015)
10.1007/978-3-662-54500-3_19
Stellenwert von CRS und HIPEC bei Mesotheliom
B. Rau (2018)
10.18632/ONCOTARGET.4253
Reactive oxygen species a double-edged sword for mesothelioma
S. Benedetti (2015)
10.3748/wjg.v20.i33.11700
Advances in the management of peritoneal mesothelioma.
A. Raza (2014)
10.1200/EdBook_AM.2013.33.182
Peritoneal mesothelioma: the site of origin matters.
H. Kindler (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar